[Acute-phase reactants and markers of inflammation in venous thromboembolic disease: correlation with clinical and evolution parameters].
OBJECTIVE
To asses the association of acute reactants and interleukin 6 and 8 (IL-6 & IL-8) at diagnosis of venous thromboembolic disease (VTD) and clinical outcome.


METHODS
100 patients were diagnosed of VTD by image tests. Acute reactants (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen), D-dimer and IL-6 and IL-8 we measured at the moment of diagnosis. We made a 12 month follow-up of these patients to notice any clinical evolution outcomes (recurrences, bleeding, post-phlebitic syndrome, death).


RESULTS
IL-6 was increased in 9 patients and IL-8 in 3. The risk factors, time to diagnosis and pulmonary embolism rate were similar in both interleukin groups (normal and high levels). Fibrinogen levels were significantly increased in high IL-6 group (585 +/- 179 vs. 485 +/- 154 mgr/dl; p = 0.05). During follow-up there were 5 deaths, 3 recurrences, 11 bleedings and 43 postphlebitic syndromes. Normal ESR level was associated to postphlebitic syndrome (17.8 +/- 14.5 vs. 31.4 +/- 27.4 mm/1st h; p = 0.016). Patients who had high levels of IL-6 had worse survival than these with normal levels (p = 0.015).


CONCLUSIONS
IL-6, ESR, and CPR at diagnosis of VTD could be useful to identified patients with higher risks of death and postphlebitic syndrome during the first year after diagnosis.
Marchena Yglesias
P J
PJ
Servicio de Medicina Interna, Hospital Virgen de la Luz, Cuenca. pjmy1@yahoo.es
Nieto Rodríguez
J A
JA
Serrano Martínez
S
S
Belinchón Moya
O
O
Cortés Carmona
A
A
Díaz de Tuesta
A
A
Bruscas Alijarde
M J
MJ
Ruiz Ribó
M D
MD
D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D015897:Comorbidity; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005500:Follow-Up Studies; D006801:Humans; D007249:Inflammation / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood / Q000175:diagnosis / Q000401:mortality; D011186:Postphlebitic Syndrome / Q000097:blood / Q000453:epidemiology; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D012307:Risk Factors; D013924:Thrombophlebitis / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D016896:Treatment Outcome
D000209:Acute-Phase Proteins; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D015850:Interleukin-6; D016209:Interleukin-8; C036309:fibrin fragment D; D005340:Fibrinogen; D002097:C-Reactive Protein